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DEREGULATION AND THE ADMINISTRATIVE
ROLE:
LOOKING AT DIETARY SUPPLEMENTS
Margaret Gilhooley*
I. INTRODUCTION
As anyone who watches television or shops in a
supermarket or drugstore knows, claims of dietary supplements
which "support mood" or achieve other effects have expanded in
recent years. This expansion is attributable to the 1994
enactment of the Dietary Supplement Health and Education Act
(DSHEA).' This statute represents the most important example
of deregulation of a federal health and safety program.
This article examines the statutory scheme and the
regulatory measures taken by the Clinton Administration to
implement federal health and safety program deregulation. The
article begins by describing the earlier pre-market approval
system for drug claims on supplements and the reasons for the
statutory change. The law now permits claims to be made for
drug-like effects of supplements on the "structure and function"
of the body, but not for disease claims.2 The Food and Drug
Administration's (FDA) recent regulation recognizing a wide
scope for structure and function claims will be assessed, along
with the adequacy of the substantiation model that has now
* Professor of Law, Seton Hall Law School; J.D. Columbia Law School. Member
of the President-appointed Commission on Dietary Supplement Labels, created by
DSHEA. Served in the Office of the Chief Counsel for the Food and Drug Administration
from 1975-81. The author wishes to thank Douglas Mehan for research assistance. This
article benefited from a research stipend from Seton Hall Law School.
1. Pub L. No. 103-417, 108 Stat. 4325 (1994) (codified as amended in scattered
sections of 21 U.S.C.). See discussion in Margaret Gilhooley, Herbal Remedies and
Dietary Supplements: The Boundaries of Drug Claims and Freedom of Choice, 49 FLA. L.
REV. 663 (1997) [hereinafter Herbal Remedies], and in the Comm'n on Dietary
Supplement Labels, Comm'n on Dietary Supplement Labels Report to the President,
Congress and the Secretary of Health and Human Services (Nov. 24, 1997) [hereinafter
Commission Report], available at<http://www.health.gov/dietsupp>.
2. 21 U.S.C. § 321(g) (1994) (structure and function claims exempt from drug
definition).
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replaced prior review. 3 The article will also take note of a
judicial decision based on constitutional grounds that permits
health claims to be made on supplements based on disclaimers,
and the FDA's action on remand.4 The policy arguments for
allowing disease claims, with disclaimers, based on consumer
choice are also noted. The policy issues about the role of choice
for supplements has a corollary in the debate about the role of
alternative medicine in relationship to conventional medical
care.
5
The deregulation of supplements has also replaced the
system of prior approval of the safety of food additives found in
supplements with a system that places the burden on the agency
to prove the supplement poses a significant safety risk.6 To
understand the agency's present authority, the pending issues
concerning the use of ephedrine in supplements for weight
control are examined. The article considers whether there are
means, other than a return to a pre-market approval system,
that would provide adequate assurance of the safety of
supplements.
The article also considers the deregulation of supplements
in the context of a larger debate about the role of administrative
regulation. Regulation is seen as "under attack," with a lack of
any "clear vision of the goals of regulatory reform."7  The
"pragmatic tradition of governance" has been described as
providing "a better conception for administrative reform" than
earlier models.8 Efforts have also been made to identify a "third
3. 21 U.S.C. § 343(r)(6) (1994) (substantiation and disclaimer for structure and
function claims), FDA Final Rule, Regulations on Statements Made for Dietary
Supplements Concerning the Effect of the Product on the Structure and Function of the
Body, 65 Fed. Reg. 999 (2000) (hereinafter Final Rule) and Part III infra.
4. Pearson v. Shalala, 164 F.3d 650, (D.C. Cir. 1999); see Part IV infra, and
Margaret Gilhooley, Constitutionalizing Food and Drug Law, 74 TUL. L. REV. 815, 841-
62 (2000).
5. Kathleen Boozang, Is the Alternative Medicine? Managed Care Apparently
Thinks So, 32 CONN. L. REV. 567 (2000), Ronald A. Chez & Wayne B. Jonas, The
Challenge of Complementary and Alternative Medicine, 177 AM. J. OBSTETRICS & GYN.
1156 (1998), and David M. Eisenberg et al., Unconventional Medicine in the United
States: Prevalence, Costs and Patterns of Use, 328 NEW ENG. J. MED. 246 (1993).
6. 21 U.S.C. § 321(s) (1994 & Supp. III 1997) (exemption from food additive
provisions); see Part VI infra.
7. Jody Freeman, Collaborative Governance in the Administrative State, 45 UCLA
L. REV. 1, 3-4 (1997).
8. Sidney A. Shapiro, Administrative Law After the Counter-Reformation:
Restoring Faith in Pragmatic Governance, 48 U. KAN. L. REV. 689 (2000). The paper
reviews the writings of a range of commentators, and notes different patterns in
viewpoints about the government's role over the past thirty years. These approaches
Vol. 62
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way" of regulation distinct from conservative or traditional
democratic approaches. 9 Measures to regulate less are also
likely to be of special interest to the Administration of the new
President.
An "alternative conception" of administration has also been
proposed, that it should be seen as "a set of negotiated
relationships," which reflects the extent of "public/private
interdependence" and the need to "grapple with private
power."10 That approach encourages agencies to participate in
"collaborative governance" through measures such as negotiated
rulemaking and voluntary self-regulation, but also recognizes a
need to assess the regulatory regimes that are a product of these
interactions. 1
Others view collaborative techniques as having only a
limited role.12 The negotiation model has also been criticized as
giving the agency the role of being just another participant in
the process, seeking consensus, rather than as having an
include the concern for beneficiaries and the public interest in the 1970's as described,
e.g, in Richard S. Stewart, The Reformation of American Administrative Law, 88 HARv.
L. REV. 1669 (1975) (emergence of administrative law as a pluralistic decision-making
process that gave attention to regulatory beneficiaries and public interest group
representatives), the criticism of government failure in the Reagan era, described, e.g., in
CASS R. SUNSTEIN, AFTER THE RIGHTS REVOLUTION: RECONCEIVING THE REGULATORY
STATE 74 (1990) (while regulatory statutes are not a failure, some regulatory strategies
produce costs that "dwarf" benefits and have "unanticipated side effects"), and the
current effort at restoration or reconciliation, described, e.g., in IAN AYRES & JOHN
BRAITHWAITE, RESPONSIVE REGULATION: TRANSCENDING THE DEREGULATION DEBATE
38-39 (1992) (responsive regulation should seek to cooperate with regulated entities as
the first strategy before commanding solutions). See also Robert L. Rabin, Federal
Regulation in Historical Perspective, 38 STAN. L. REV. 1180 (1986) (tracing developments
beginning in the Populist era and New Deal).
9. Shapiro, supra note 8, at 689 (citing President Clinton and Prime Minister
Blair's proposal for a "third way" of government). See also Robert B. Reich, Where
Clinton's Third Way Went Wrong, HARPER'S MAGAZINE April 1999, at 5 (describing the
Third Way as having gone beyond finding a middle ground between capitalism and
communism to seeking policies equidistant from Margaret Thatcher conservatism and
pre-New Democrat approaches; while there is "no formal statement of principles," this
program includes "deregulation and privatization" and a belief that economic growth and
free trade can provide security and make the economically displaced "winners").
10. Jody Freeman, The Private Role in Public Governance, 75 N.Y.U. L. REV. 543,
545 (2000).
11. Id. at 199; See also Jody Freeman, Private Parties, Public Functions and the
New Administrative Law, 52 ADMIN. L. REV. 813, 857 (2000).
12. Mark Seidenfeld, Empowering Stakeholders: The Limits on Collaboration as
the Basis for Flexible Regulation, 41 WM. & MARY L. REV. 411 (2000); cf. Barry Boyer &
Errol Meidinger, Privatizing Regulatory Enforcement: A Preliminary Assessment of
Citizen Suits under Federal Environment Laws, 34 BUFF. L. REV. 833, 836-37 (1985)
(potential for a "major-perhaps permanent realignment of roles and powers with
respect to private and public enforcement of the law").
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independent responsibility to implement the statute, a
responsibility for which it is accountable. 13  Delegation to
agencies has also been seen as having a positive role, with the
agency having the power to participate actively in an ongoing
process of constructing legislative meaning. 14
This article does not deal with the overall direction of
administrative reform or regulatory theory, nor with the
collaborative role that private parties have or might have in the
general area of food and drug regulation with respect to drug
approvals and agency review of food additives.' 5
Instead the focus is on dietary supplements because they
represent an important example of how changes, mandated by
Congress, have affected the rationale and form of regulation for
a major category of consumer products. The substantive
deregulation has fundamentally shifted the public and private
roles with respect to the availability of supplements. The
supplements represent a test of the public's acceptance of
deregulation and the role of individual choice. The experience
with supplements may lead to a further unraveling of the pre-
13. William Funk, Bargaining Toward the New Millennium: Regulatory
Negotiation and the Subversion of the Public Interest, 46 DUKE L.J. 1351, 1356 (1997)
(the principles of negotiated rulemaking "subtly subvert the basic underlying concept of
American administrative law"). See also Daniel A. Farber, Democracy and Disgust:
Reflections on Public Choice, 65 CHI.-KENT L. REV. 161, 163, 174 (1989) (criticizing an
early version of the public choice theory that views the political process as solely self-
seeking).
14. Jerry L. Mashaw, Greed, Chaos and Governance at 148, 204 (1997). While
public choice can offer insights, some theorists have a bleak vision in which legislators
use the administrative process to deliver on deals that maintain them in office. Id. at
109. Agencies, though, are constrained by legal rules and rationality review, and are
expected to be responsive to the policy issues of a nationally-elected President. Id. at
152-57. Moreover, game theorists view preferences as static, but the agency
implementation can influence the way legislators view their actions and preferences. Id.
at 204.
15. There has been an active debate about giving third party reviews presumptive
weight in drug approvals. See Richard A. Merrill, The Architecture of Government
Regulation of Medical Products, 82 VA. L. REV. 1753, 1857-64 (1996); Margaret
Gilhooley, The Administrative Conference and the Progress of Food and Drug Reform, 30
ARIz. ST. L. J. 129, 133-41 (1998). Regulated entities can also make their own
determination, subject to the risk of enforcement action, that a food additive does not
need prior review by the agency because it is generally recognized as safe (GRAS). See
Lars Noah & Richard A. Merrill, Starting From Scratch: Reinventing the Food Additive
Approval Process, 78 B.U. L. REV. 329, 441-43 (1998). FDA has proposed requiring pre-
market notification of genetically-modified foods, but continues to regard transferred
genetic material as presumptively GRAS and not subject to pre-market approval. FDA
Proposed Rule, Premarket Notice Concerning Bioengineeered Foods, 66 Fed. Reg. 4706,
4709 (2001); Alliance for Bio-Integrity v. Shalala, 116 F. Supp. 2d 166 (D.D.C. 2000)
(upholding FDA presumption).
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market approval system for foods and drugs, and possibly other
consumer products. Out of a concern of "being DSHEA'ed" in
other areas by Congress, the FDA may be more willing to pursue
collaborative measures with regulated entities and alternative
approaches. Moreover, this study of how dietary supplements
have been regulated can serve as a benchmark in judging the
impact of the new Administration from a different party.
The examination of the regulation of supplements concludes
with some reflections on the wider debate about regulation and
the administrative role in this context. Dietary supplement
manufacturers are required to substantiate their claims for the
products, but need not obtain any pre-market approval. Can
substantiation be a "third way" of regulation that provides an
intermediate model to ensure that the supplements work? The
safety of supplements is an even more basic concern. Would the
substantiation model be better at ensuring the safety of
supplements than the present provisions which put the burden
on the agency to demonstrate risks? What is needed to make
the substantiation process an effective one? How does the
deregulation of supplements affect the agency's mission under
its delegated authority?
II. STATUTORY DEREGULATION OF SUPPLEMENTS CLAIMS
BEFORE DSHEA
A. Pre-market Approval Model for Drug Claims
Before DSHEA, a dietary supplement could only make a
drug claim if the manufacturer obtained pre-market approval
from the FDA showing that the product was safe and effective. 16
That licensing process is a lengthy one that involves
establishing that the claims are supported by "adequate and
well-controlled investigations."17  Thus, supplements were
subject, in theory, to one of the most rigorous models for
regulation.
Drug claims fall into two categories. The first, and most
familiar category, relates to therapeutic claims to prevent or
treat disease. The second category covers claims to "affect the
structure or function of the body."' 8 The drug definition was
16. 21 U.S.C. § 355(d) (1994).
17. 21 U.S.C. § 355(d) (1994). See Merrill, supra note 15.
18. 21 U.S.C. § 321 (g)(1)(C) (1994 & Supp. III 1997).
2001
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broadened in 1938 to cover these additional claims in order to
reach weight reduction products. At that time, obesity was not
considered a disease, and the expansion was necessary to reach
claims for slenderizing effects, and "to make possible the
regulation of a great many products" that do not treat disease. 19
Claims to affect the structure and function of the body also
include products concerned with physical difficulties, such as
sleep-aids, or tranquilizers, as well as products that produce
recreational effects. 20
B. Supplements Sold As Foods: Scope of Food Claims and Pre-
market Approval
1. Limits of Food Structure and Function Claims
Dietary supplements were typically sold as foods. Foods
and supplements could not make disease claims without
complying with the requirements for pre-market approval of
drugs.21  Whether they could make structure and function
claims was more complicated. Foods are exempt from being
considered drugs when they claim to effect the structure and
function of the body. Foods inherently have these effects. 22
Supplements could only get the benefit of the food exemption,
however, if these claims related to uses of foods, such as taste,
aroma, or nutrition.23 As a result, supplements, like the familiar
vitamins and minerals, could make claims about their
nutritional effects (e.g. calcium builds strong bones), but other
claims about the effects of supplements, such as to reduce
weight by blocking absorption of starch, were considered drug
claims. 24 This nutritional test for food claims limited the scope
19. Nutrilab, Inc. v. Schweiker, 713 F.2d 335, 336 (7th Cir. 1983) (weight control
products), quoting Hearings on S.1944 before a Subcommittee of Senate Comm. on
Commerce, 73rd Cong., 2d Sess. 15-16. (Statement of Walter G. Campbell, Chief of FDA,
1933). See infra Part III.B.3 for FDA's current position that some weight reductions are
not disease-related.
20. The wider recreational effects were the basis for FDA's effort to regulate
tobacco as a drug and medical device. FDA regulation of tobacco was found statutorily
invalid in Food and Drug Admin. v. Brown & Williamson, 590 U.S. 120 (2000). The
Supreme Court found tobacco not to be a drug relying on Congressional intent to exclude
tobacco from regulation, in the absence of disease claims, rather than any general
limitation of the scope of the drug definition.
21. 21 U.S.C. § 321(g)(1)(B) (1994).
22. 21 U.S.C. § 321(g)(1)(C) (1994 & Supp. III 1997).
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of claims which could be made by supplements without meeting
the drug approval requirements.
2. Scope of Food Additive Pre-Market Approval Requirements
With respect to safety, supplements sold as foods were
subject to pre-market approval as food additives if an ingredient
was added to other foods, and if it was not generally recognized
as safe (GRAS).25 Obtaining approval for food additives is also a
lengthy process and approval can be difficult to obtain.26
Nutritional supplements such as vitamins and minerals are
ordinarily considered GRAS, and can be sold without the need
for prior agency review. Other dietary supplements sold as
foods were potentially subject to the need for prior agency
approval.
The scope of the food additive provisions was tested when
the FDA challenged as an additive a supplement containing only
black currant oil in a capsule made of gelatin, an inert food
substance. The court rejected the FDA effort and described as
"Alice-in-Wonderland" the position that putting the black
currant oil in a gelatin capsule constituted the addition of foods
to each other.27 Rather, the oil should be considered as a food
sold in its individual form, making it subject to the less-rigorous
safety standards governing raw agricultural products and other
"non-added" foods.28
C. Enforcement Discretion Model: Non-Regulation and the
Portent of Increased Regulation
Notwithstanding the theoretical rigor of the regulatory
scheme applicable to supplements, in practice, the FDA's
enforcement was limited in scope.29 In the 1970's, the FDA
25. 21 U.S.C. § 321(s) (1994).
26. Lars Noah & Richard A. Merrill,supra note 15.
27. United States v. Two Plastic Drums, 984 F.2d 814, 819 (7th Cir. 1993), For a
similar result see United States v. 29 Cartons of. . .An Art. of Food, 987 F.2d 33 (1st Cir.
1993). FDA's position may have had merit, nonetheless, since packaging a food in a
capsule affects the palatability of the contents, and thus affects that characteristic of the
food, an element of the food additive definition. 21 U.S.C. § 321(s) (1994).
28. 21 U.S.C. § 342(a)(1) (1994); United States v. 1232 Cases American Beauty
Brand Oysters, 43 F. Supp. 749 (W.D. Mo. 1942).
29. General Accounting Office Report to Senator Kennedy, at 4 (B252966, July 2.
1993) [hereinafter GAO Report] reprinted in I. SCOTT BASS & ANTHONY L. YOUNG,
DIETARY SUPPLEMENT HEALTH AND EDUCATION ACT: A LEGISLATIVE HISTORY AND
ANALYSIS 297, 300 (1996) (published by the Food and Drug Law Institute).
2001
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sought to regulate high doses of nutritional supplements and
"irrational combinations" as drug products implicitly intended to
treat or prevent diseases. 30  The FDA's effort led to a
Congressional repeal of the agency's authority to classify
supplements as drugs based on dose or combinations. 31
Thereafter, the FDA did not "systematically" regulate
supplements; the agency acted in response to safety problems or
express drug claims, rather than insisting on prior proof of lack
of harm.3 2 Over time, non-food products also came to be sold as
dietary supplements, some of which may have had a history of
use in traditional medicines. 33
The FDA's regulatory approach changed when 38 deaths
and 1500 adverse effects were attributed to the use of the non-
essential amino acid, L-tryptophan. 34 Commissioner David
Kessler of the FDA had a Task Force consider options for
dealing not only with L-tryptophan but also with the range of
issues presented by dietary supplements. 35 The Task Force
considered the amino acid to be an unapproved food additive
because of its safety risks, one which needed to be addressed by
FDA regulatory action.36 In addition, the Report viewed the
supplement as an unapproved drug based on its marketing
claims to support the immune function, to be "nature's
tranquilizer," and to treat schizophrenia and senility. 37
The Task Force also discussed "issues of concern" about
herbal supplements, and identified the FDA's immediate goal as
ensuring removal of hazardous products and products marketed
for drug uses in accordance with the agency's health fraud
program.38 The Task Force may have intended only selective
enforcement to deal with major frauds and safety risks, since it
sought to provide "some accommodation of the desire of a
substantial segment of the public to obtain dietary supplements,
30. Herbal Remedies, supra note 1, at 673-75.
31. 21 U.S.C. § 350 (1994).
32. GAO Report, supra note 29, at 4.
33. FDA Advance Notice of Proposed Rulemaking, Regulation of Dietary
Supplements, 58 Fed. Reg. 33,690, at 33,698-99 [hereinafter Advance Notice].
34. Id. at 33,690-92.
35. Id. at 33,694-99.
36. Id. at 33,698; Herbal Remedies, supra note 1, at 677-78 (1997).
37. See Advance Notice, 58 Fed. Reg. at 33,697. The claims to support the immune
system, and claims to reduce stress or support mood would now be permissible under
DSHEA. See infra Part III.B.2, III.B.3.
38. See Advance Notice, 58 Fed. Reg. at 33,698.
Vol. 62
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including ones with little or no documented nutritive value."3 9
The dietary supplement industry portrayed the FDA
approach in terms of its broadest possible reach as having the
potential to take vitamins and minerals away from the public.40
A national blackout day was organized in which retailers
covered in black crepe all the supplements that might be
removed from sale if the FDA pursued an expansive view of its
regulatory authority.41 The public reaction "galvanized support"
for the legislation that became DSHEA.42
D. Reasons for DSHEA and Lessons for Regulatory Reform
DSHEA was enacted, not by a Republican Congress, but by
a Democratically controlled Congress, and was signed by a
Democratic President on the eve of the 1994 election. 43 The
principal spur for the law was public reaction to the FDA Task
Force's plans to address safety problems posed by L-tryptophan
and other supplements, a plan which could be read to impose the
rigors of pre-market review to broad numbers of supplements.44
There were other factors. The FDA's regulations on health
claims allowed claims for foods, but no claims for nutritional
supplements, furthering the perception that the FDA was
prejudiced against supplements. 45 The cases the FDA had
brought against dietary supplements complicated the agency's
position. The categorization of the FDA's position on the scope
of the food additive provisions as "Alice-in-Wonderland"
contributed to a perception of an overzealous agency. 46 The
FDA's judicial success in establishing that supplements sold as
food had to have nutritional value concerned the industry
39. Id. at 33,691.
40. Bass & Young, supra note 29, at 28.
41. Id. See also Michael Weisskopf, In the Vitamin Wars, Industry Marshals an
Army of Citizen Protesters, WASH. POST, Sept. 14, 1993, at A7 (reporting on campaign,
the slogan of "Don't Let Health Freedom Follow the Dinosaur," role of Senator Hatch,
and industry lobbying).
42. Bass and Young, supra note 29, at 7.
43. DSHEA was enacted on Oct. 25, 1994, Pub. L. No. 103-417. The Republican
Party won a majority in Congress in the November election. See Adam Clymer, G.O.P.
Celebrates Its Sweep to Power, President Clinton Vows to Find Common Ground, N. Y.
TIMES, Nov. 10, 1994, at Al.
44. Bass and Young, supra note 29, at 7, 26-28. See also FDA Advance Notice, 58
Fed. Reg.33,690.
45. Food Labeling; General Requirements for Health Claims 59 Fed. Reg. 395
(1994) (to be codified at 21 C.F.R. 101.4).
46. See supra note 21 and accompanying text.
2001
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because it narrowed the scope of permissible claims. 47
The passage of DSHEA has been described as Commissioner
Kessler's "greatest failure" as the head of the FDA. He viewed
supplements as being one of the "problems you are not going to
solve."48 The problem, on the one hand, is that the agency had
concerns with preventing safety risks from supplements like L-
tryptophan, and, in pursuit of its protective public health
mission, identified how its authority, if exercised fully, could be
used to limit the supplement as a food additive and as a drug.
This authority, if pursued and fully applied to that and other
supplements, would end the truce provided by the FDA's
enforcement discretion, allowing supplements to be sold simply
as supplements in the absence of express drug claims of some
identified specific safety risk.
The dietary supplement industry, though, probably wanted
more than a return to a state of truce. Herbal remedies had a
potential for a greater market, as demonstrated by their
popularity in Europe as well as Asia.49 To broaden the appeal of
the products and to advertise effectively to a mass audience, the
manufacturers needed to be able to make express claims about
the usefulness of the products for drug purposes. Some
supplement proponents sought to have Congress allow express
disease claims to be made for supplements, so long as there was
substantiation. 50  While Congress expanded the claims for
supplements, it did not go as far as allowing disease claims.51
Perhaps the agency could have made greater commitments
47. See supra note 18.
48. Marion Burros, F.D.A. Commissioner Is Resigning After 6 Stormy Years in
Office, N. Y. Times, Nov. 26, 1996, at Al.
49. Edgar R. Cataxinos, Note, Regulation of Herbal Medications in the United
States: Germany Provides a Model for Reform, 1995 UTAH L. REV. 561; Commission
Report, supra note 1, at 49-54.
50. Dietary Supplement Health and Education Act: Is the FDA Trying to Change
the Intent of Congress? Hearing before the House Comm. on Gov't Reform, 106th Cong.
58 (1999) (remarks of ranking Democratic member Cong. Waxman) [hereinafter
Hearings]:
When we drafted this legislation, there were some people who argued a
manufacturer ought to be able to sell a product and make any claim that he
wants to if he has some substantiation ... And let the marketplace operate. On
the other hand, other people felt, well, that is just too wide open. And we made
a distinction in the law between disease claims. . And we said those products
are drugs and they ought to be reviewed by FDA to be sure they are safe and
effective. But if it is a product that simply is intended to affect the structure
and function of the body, we said the manufacturer can make claims in that
regard.
51. 21 U.S.C. § 343(r)(6) (1994).
Vol. 62
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about the limited scope of its regulatory intentions. Perhaps
regulatory negotiations or compromises might have forestalled
Congressional action. One lesson may be that when
enforcement discretion is used as an "accommodation" to those
resistant to greater regulation, the agency needs to provide
advice clearly not only on the high priorities for enforcement
action, but also on those matters of lesser regulatory concern.5 2
Most relevant now is that Congress has rewritten the
regulatory scheme for supplements. The agency has to
implement the law mindful of the Congressional decision to
allow more scope for supplement claims. Still, Congress has
kept supplements within the framework of FDA regulation. The
agency needs to reexamine and reformulate how its public
health mission relates to the expanded scope for claims. If
agency regulation is to be seen as an effort at problem-solving,
the deregulation of supplements provides a challenge in how to
reconcile the expansion of claims with the agency's traditional
core responsibilities of preventing harm and deception from
personal use products.
III. SCOPE OF REGULATION OF SUPPLEMENT CLAIMS UNDER
DSHEA
A. DSHEA Provisions on Claims
A major change made by DSHEA is to allow dietary
supplements to make statements about the role of a "dietary
ingredient" in affecting "the structure or function of the body"
without the statement being considered a drug claim.53 To be
permitted, the claim has to be accompanied by a disclosure that
the "statement has not been evaluated by [the FDA]" and the
product "is not intended to diagnose, treat, cure, or prevent
disease."54 The statement has to be substantiated, but no prior
FDA approval is needed, as would be necessary for a drug
claim. 55 The claims can be made not only for nutrients, but also
for "dietary ingredients."56 This language indicates that claims
52. See infra Part II.A.3 and Part V.B.6. However, firm commitments by the
agency not to take enforcement action necessitates the use of rulemaking procedures. See
Community Nutrition Institute v. Young, 818 F.2d 943 (D.C. Cir. 1987).
53. 21 U.S.C. § 343(r)(6)(A) (1994).
54. 21 U.S.C. § 343(r)(6)(C) (1994).
55. 21 U.S.C. § 343(r)(6)(B) (1994).
56. 21 U.S.C. § 343(r)(6)(A) (1994).
2001
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for supplements are permitted even though the claim does not
relate to nutrition. Thus, nutritional value, the prior test for an
appropriate food supplement claim, is no longer a restraint.57
The effect of DSHEA is to allow herbs, botanical and other
products to be sold as dietary supplements and to make claims
about their effects even though they are not foods in any
nutritional sense and even though they may have had a history
of use in traditional medicine in other countries.
B. FDA Regulations on Structure and Function Claims
DSHEA poses a challenge, indeed an enigma, on how to
distinguish disease claims from structure and function claims.
As the FDA has stated, diseases, "by definition, adversely affect
some structure and function of the body, and it is possible to
describe most products intended to treat or prevent disease in
terms of their effects on the structure and function of the
body."58 While distinguishing between disease and structure
and function claims matters little for purposes of drug
regulation, since both claims are subject to pre-market approval,
the passage of DSHEA has necessitated a difficult feat of line-
drawing for supplement claims.59
In its rulemaking, completed in January 2000, the FDA
identified several major factors for drawing the boundary
between disease claims and permissible structure and function
claims for dietary supplements.60  The FDA rules are
complicated and deal with a great variety of claims. This
discussion highlights the major themes. The examples used are
often as illuminating as the tests in understanding the overall
pattern.
1. Implied References to Specific Diseases Versus Broad
References to Body Systems
The supplement industry argued that a claim is a disease
57. Cf. Nutrilab, Inc., 713 F.2d at 335.
58. Proposed Rule, Regulations on Statements Made for Dietary Supplements
Concerning the Effect of the Product on the Structure or Function of the Body, 82 Fed.
Reg. 23624 (1998) (proposed April 29, 1998) [hereinafter Proposed Claims Rule].
59. The 1962 Drug Efficacy Amendments required pre-market approval for drug
claims in the wake of the thalidomide crisis. The Act extended to both therapeutic and
structure and function claims.
60. FDA Final Rule, Regulations on Statements Made for Dietary Supplements
Concerning the Effect of the Product on the Structure and Function of the Body, 65 Fed.
Reg. 999 (2000) (to be codified at 21 C.F.R. pt. 101)[hereinafter Final Claims Rule].
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claim only if it makes an express reference to a disease. In
support, the industry maintained that Congress required a
disclaimer on supplements because Congress understood that
the effects of specific diseases "can also be described" as
structure and function effects and resolved the "tension" by
requiring the disclaimer, leaving it to the consumer to decide. 61
The FDA rejected that position and found implied disease claims
are precluded for supplements, since implied claims would
contradict and eviscerate the disclaimer and cause confusion.62
On the other hand, the FDA regards as disease claims
statements that refer to specific diseases, but not statements
that "refer broadly to body systems or functions without
sufficient reference to specific abnormalities or symptoms to be
understood as references to particular diseases."63 As a result,
the FDA accepts as permissible structure and function claims
statements that a product "helps maintain cardiovascular
function", or "promotes relaxation."4
2. Changing Abnormal Function Versus Maintaining Function.
Under another test, the FDA regards as an implicit disease
claim references to abnormal conditions, or to the "characteristic
signs or symptoms" of a specific disease. The agency gives the
following examples of disease claims: "lowers cholesterol,"
"reduces joint pain" (a characteristic of arthritis), or "improves
urine flow in men over 50" (a characteristic of benign prostatic
hypertrophy).65
On the other hand, the FDA regards as non-disease claims
statements that a product maintains bodily functions, such as
"helps maintain a healthy lung function," "reduces stress and
frustration," or "improves absentmindedness."66 The FDA's
rationale is that some signs and symptoms, such as
absentmindedness, "may be associated with a number of
diseases, but are not, by themselves, sufficient to characterize
61. Id. at 1012-13.
62. Id. at 1013-14.
63. Proposed Claims Rule, 82 Fed. Reg. at 23,626; see generally Final Claims Rule,
65 Fed. Reg. at 1015, § 37 (emphasis added).
64. These claims were recognized as appropriate in the Proposed Claims Rule, 82
Fed. Reg at 23626, a recognition not changed by the Final Claims Rule.
65. Final Claims Rule, 65 Fed. Reg. at 1016; 21 C.F.R. § 101.93(g)(2)(ii).
66. Proposed Claims Rule, 82 Fed. Reg at 23,626; Final Claims Rule, 65 Fed. Reg.
at 1018-19; 21 C.F.R. § 101.93(g)(2).
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specific diseases. '67
Under this approach, while claims to lower cholesterol are a
disease claim, maintaining cholesterol is a supplement claim. In
the case of cholesterol, though, in response to comments, the
FDA believes that the maintenance claim should say, "helps to
maintain cholesterol levels that are already within the normal
range."68
The final rule also deleted, as too vague, the proposal's
identification of disease in terms of signs and symptoms
recognizable to professionals and consumers. The final rule
looks at whether the labeling refers to signs and symptoms of
disease, in lay or professional language, without considering
recognizability. 69  The change seems to make consumer
confusion about the scope of the labeling claim less significant.
3. Substitutes for Drug Therapy versus Other Functions
A claim is a disease claim if it suggests that the product is a
substitute for a recognized drug use, such as a claim to be an
Herbal Prozac or an antibiotic or antiviral.70
However, a claim that a supplement "supports the immune
function" is not a disease claim. This is because it does "not
identify a specific drug... action," and makes "general references
to an effect on a body system that has several functions, only one
of which is resistance to disease."71 The other functions include
the role of white blood cells in disposing of aging red blood cells
and damaged cells. 72
The FDA also found that an "appetite suppressant" claim or
a claim for "use in your weight loss plan" is a structure and
function claim. Even though obesity is a disease, merely being
overweight is not, and the claims are permissible when the
context makes clear it is for ordinary weight loss. 73
A claim to "help increase muscle mass" falls in the structure
67. Proposed Claims Rule, 82 Fed. Reg at 23,626. See also Final Claims Rule, 65
Fed. Reg. at 1016.
68. Final Claims Rule, 65 Fed. Reg. at 1019. The author made comments
supporting this change. Letter to FDA Dockets Management Branch, on Docket 98N-
0044, Dietary Supplements, July 29, 1999 (on file with the author).
69. Final Claims Rule, 65 Fed. Reg. at 1016; 21 C.F.R. § 101.93(f)(2)(ii).
70. Final Claims Rule, 65 Fed. Reg. at 1015.
71. Proposed Claims Rule, 82 Fed. Reg. at 23,627. See also responses to comments
in Final Claims Rule, 65 Fed. Reg. at 1028, including comments of author.
72. Final Claims Rule, 65 Fed. Reg. at 1029.
73. Final Claims Rule, 65 Fed. Reg. at 1026-27.
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and function category. However, the effect implied may be one
for an anabolic steroid, and thus be subject to the Controlled
Substances Act.74
4. Natural States
The FDA's final rule is significantly more expansive than its
proposal because it permits claims about "common, mild
symptoms associated with normal life stages." Supplements can
now claim usefulness for conditions associated with aging such
as "hot flashes," "wrinkles," "mild memory problems," "hair loss,"
and "inability to change eye focus from near to far (or vice
versa). '75 Also acceptable is a claim for "decreased sexual
function associated with aging."76 The claims are considered
disease claims only if they affect an abnormal condition that "is
uncommon or can cause significant or permanent damage."77
5. OTC Nonspecific Conditions and Various Causes
The FDA's final rule also accepted as non-disease claims a
number of claims made for over-the-counter drugs. Acceptable
claims include "occasional heartburn," "for relief of occasional
sleeplessness," and for "nausea... associated with motion."78 On
the other hand, in a tougher call, the FDA did not consider nasal
decongestant claims to be permissible because they relate to the
characteristic symptoms of diseases such as colds, flu and hay
fever. 79
6. Disease Definition
The FDA's final rule adopted a different definition of
disease than'the proposal, which had relied on a medical
dictionary definition.80 The final rule accepted the position
74. Id. at 1030, § 84 (citing 21 U.S.C. § 802(41) (1994)). FDA has also recently
issued guidance that claims to be alternatives to illicit street drugs and for recreational
purposes to affect psychological states, such as "to get high," are not dietary supplement
claims since the claims do not relate to supplementing the diet. Notice, Availability of
Guidance, Street Drug Alternatives, 65 Fed. Reg. 17,512 (Apr. 3, 2000).
75. Final Claims Rule, 65 Fed. Reg. at 1020.
76. Id. at 1020. A claim to be an herbal Viagra would not be permissible under the
criteria stated.
77. 21 C.F.R. § 101.93 (g)(2)(iii), as added by Final Claims Rule, 65 Fed. Reg. at
1050.
78. Final Claims Rule, 65 Fed. Reg. at 1031.
79. Id.
80. Proposed Claims Rule, 82 Fed. Reg. 23,624, 23,625 (1998).
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urged in the comments and relied, instead, on a regulatory
definition used in implementing the statute on health claims for
foods. The FDA's final rule discusses the differences between
the definitions in considerable detail.8' The principal
significance seems to be that the definition adopted in the final
rule uses the term "damage" to identify a disease, a term the
proposal did not use because of a concern that the term could
limit diseases to those which were "serious or long-term."8 2 The
FDA intended the final rule to be more permissive than the
proposal, and the change in the definition seems related to the
decision to allow claims about natural states which are mild and
that do not cause significant or permanent harm.83
C. Right Line?
1. Dietary Role As Test
One question is whether the FDA Rule draws an
appropriate line between permitted and unpermitted claims.
Previously I suggested that structure and function claims should
be "dietary" in some meaningful sense, such as being a claim to
have a food-like effect on the body, like providing energy, or an
alertness effect, similar to that from coffee, but that the claims
not be for drug-like effects such as improving
absentmindedness8 4 The FDA rejected that distinction.8 5
DSHEA is an ambiguous statute, and it is understandable,
if not entirely satisfactory, that the FDA took a more expansive
approach. The FDA received over 235,000 comments on its
proposed rule, most urging expanding the permitted claims.8 6
Congress also held hearings to consider whether the FDA was
misinterpreting DSHEA by being too restrictive.87 The agency's
familiarity with the history of the enactment of DSHEA also
provides support that "dietary" has a wider meaning, and that
Congress indeed intended to split the drug definition in half.
There remains, though, something odd and unsettling about
81. Final Claims Rule, 65 Fed. Reg. at 1009-10.
82. Id. at 1009-10 (disease definition).
83. Id. at 999 (intent to expand permitted claims).
84. Herbal Remedies, supra note 1, at 690-92; see also Testimony of Margaret
Gilhooley at Hearings, supra note 50, at 138,140.
85. Final Claims Rule, 65 Fed. Reg. at 1011.
86. Id. at 1000.
87. Hearings, supra note 54.
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calling products and claims "dietary" when they do not relate to
foods. The "dietary supplement" designation now serves largely
to mark out a special category of non-foods whose claims need
special evaluation by consumers.
2. Seriousness and Consumer Ability to Evaluate
The FDA's rule was influenced by another test that makes
sense in this context, whether the claim suggests use for "a
serious health condition that is beyond the ability of the
consumer to evaluate."88 That test was identified in the report
of a Presidential-appointed Commission on Dietary Supplement
Labels (Commission) on which I served, and in my comments on
the rule.89 The FDA stated it paid "particularly close attention"
to claims which relate to "serious health conditions that patients
cannot safely evaluate on their own."90
The FDA also viewed safety as one of the "major purposes"
of its rule. The FDA wanted to ensure supplements did not
make disease claims because such claims can harm consumers if
they induce substitution of "ineffective or less effective
treatments for a proven one, especially if the disease involved is
serious or life-threatening."91
3. Application Difficulties
a. Effects Beyond Consumer Assessment
While the tests used by the FDA seem justifiable, in trying
to make sense of the puzzle, the FDA has not always applied the
principles correctly. Some claims seem inappropriate, such as
the FDA's initial acceptance of claims to treat "morning
sickness." The FDA is reconsidering this claim, in view of the
potential for safety risks to the baby, an effect that is beyond the
ability of the mother to evaluate.92
Moreover, claims to "help maintain cardiovascular function"
88. Final Claims Rule, 65 Fed. Reg. at 1018; Commission Report, supra note 1 at
38, 39.
89. See Commission Report, supra note 1, at viii and 38; and Letter of Margaret
Gilhooley to FDA Dockets Management Branch (July 29, 1999) (available from the
author).
90. Final Claims Rule, 65 Fed. Reg. at 1011.
91. Id. at 1003.
92. FDA Statement Concerning Structure/Function Rule and Pregnancy Claims,
(visited Feb. 9, 2000) <http://www.fda.gov>.
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or "maintain lung function" are beyond the consumer's ability to
assess and they relate to important physical functions. Claims
of this type are more appropriately considered a disease claim.
As a disease claim, agency approval would be needed, thus
providing an added assurance of reliability and adequate
testing.9 3 Supplement labeling of "non-disease" claims has been
described as having risen to "an art form of doublespeak," with
medical uses "merely insinuated" but, nonetheless, still clear as
in the case of claims to "promote prostate health."94
It may be thought that claims like maintaining
cardiovascular health do not need the additional assurances of
reliability required for disease claims since the claim relates
only to the continuation of a normal state of functioning.
However, the line between maintenance and disease prevention
overlaps in this context. Consumers may view the product as
needed to maintain the function and prevent deterioration. The
claim may divert consumers from other proven means of
maintaining the function, and thus increase risks of harm.
Even if an adverse safety impact cannot be established,
allowing the claim is objectionable, if unsupported, because of its
ability to deceive lay users about a matter they view as
important to their health but which is beyond their ability to
assess. Providing the safeguards of pre-market approval and
testing simply to prevent deception, even if a safety impact
cannot be proven, is an appropriate and traditional regulatory
role. Whether the alternative of substantiation provided by
DSHEA is adequate to protect the public with respect to such
implied disease prevention claims is open to debate. The impact
on the public is also affected by the criteria for and priority
given to the implementation of the substantiation requirement. 95
Consumers would also be better protected if the labeling for
these maintenance supplement claims indicated the product
should be used when there is assurance the body function is
normal, and the types of symptoms which indicate the need for
93. It is true that other claims about important functions, such as cholesterol
reduction, are made directly to consumers on foods, but, by statute, the claim can only be
made based on scientific acceptance and agency approval. 21 U.S.C. § 343(r). See infra
Part IV and Pearson v. Shalala, 164 F.3d 650 (D.C. Cir. 1999) for a discussion of the
allowance of health claims on supplements, based on constitutional grounds, without
that level of support, based on disclaimers.
94. Editorial, Alternative Medicine-The Risk of Untested and Unregulated
Remedies, 339 NEW ENG. J. MED. 839, 841 (1998).
95. See infra Part III.D. The adequacy of disclaimers and labeling to prevent
deception is discussed infra Parts IV.A.3 and V.B.
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further medical advice. Claims to maintain cholesterol
functioning, for example, have less risk of deception now that
the claim is to indicate that the product is for use by those with
normal cholesterol levels.96 Whether labeling can adequately
communicate the range of normal use for the various health
function claims permitted for supplements is another question.
Supplements may be popular because some consumers find
the effort to uncover an off-label "real" use as empowering and
providing access to a hidden means to affect their health. Other
consumers may be wary of claims that are not clearly stated on
the label, and, for them, the generality of supplement claims
may serve indirectly as a caution and safeguard. The FDA's
acceptance of generality in supplement claims can be seen as
simply needed to accommodate the Congressional intent of
permitting expanded uses for consumers. The generality has its
drawbacks though, in leading to consumer confusion and the
risk of inappropriate use of supplements. Whether consumers
would be better off if supplements could expressly make disease
claims with adequate disclosures about the basis for the claims,
as some maintain, is discussed later, along with the difficulties
in identifying what is an adequate disclosure. 97
b. Generality and Need for Better Labeling
The generality of some of the permissible claims is
unsettling in other ways. For example, FDA considers claims to
be non-disease claims if the claim relates to several functions
which include disease and non-disease functions. On this basis,
the FDA recognizes a claim to "support the immune function" as
appropriate. The claim may still suggest usefulness for
infections, colds, or possibly for immune deficiency diseases like
AIDS. An ingredient sold with the immune support claim, for
example, is recognized in a World Health Organization
monograph "as an immunostimulant, supportative therapy for
colds and infections .... 9 8  When an ingredient has dual
functions, the supplement claim should be stated in terms that
are specifically limited to the non-disease use. The non-disease
96. See supra note 53 (discussion of cholesterol maintenance claims and author's
comments).
97. See infra Part V on traditional medicines and disclosures.
98. World Health Organization Draft Monographs on Botanical, Geneva,
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function involved in the immune system claim seems to relate to
supporting white blood cells in their ordinary function of
removing damaged blood cells. 99 The immune system claim for
supplements should not be a general claim but one that
identifies the limited role. The claim should state the product
maintains the immune system by supporting the ordinary role of
white blood cells in removing damaged blood cells.
Better labeling may also help in some cases to prevent
confusion about the generality or other aspects of supplement
claims. For example, the general claim to "improve
absentmindedness" should indicate that it relates to "ordinary
minor absentmindedness" to avoid an implication that it helps
with more serious conditions, including Alzheimer's disease.
The claim to help eye focus should alert consumers, with some
specificity, when they need to seek professional advice about the
condition. Claims for conditions related to life-stages should
relate to relief of symptoms recognizable to consumers when the
condition occurs, rather than prevention, a matter beyond ready
appraisal by the user, and one that leads to long-term use with
its greater implications for safety.
c. Congestion Claim as Illustrative of Choices
The FDA's restrictive treatment of nasal congestion as a
disease claim seems puzzling and problematic, and warrants
some discussion, notwithstanding the mundaneness of the
claim, because it illustrates the choices underlying the various
tests. The FDA considers the claim to be a disease claim
because congestion is a characteristic symptom of diseases like
colds, flu and hay fever. 100 This criteria focuses on medically
recognized symptoms. If one focuses on a different criteria, the
seriousness of the condition, and the role of lay judgment, the
result could be different. While claims to prevent colds can be
considered a disease claim, treating the symptoms of colds, once
99. Compare supra notes 55-56. Food manufacturers also maintain that they
should be able to make the same structure and function claims that are permitted for
dietary supplements, without the claim being considered a disease claim. FDA has
advised that it is likely to interpret the line in a similar way, although the claims may
only be permissible for foods with respect to their nutritional value. Final Claims Rule,
65 Fed. Reg. 999, 1034 (2000); Nutrilab v. Schweiker, 713 F. 2d 335, 338 (7th Cir. 1983),
discussed in Part II.A. Compare Jeannie Perron & Eugene I. Lambert, DSHEA and
Structure and Function Claims for Animal Feed, 555 FOOD & DRUG L. J. 151, 153 (2000)
(discussion of claims for sterol esters).
100. Final Claims Rule, 65 Fed. Reg. at 1031.
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the condition occurs, seems within the ordinary ability of
consumers to judge, and something which could be a supplement
claim. The ability of the consumer to assess the claim from
experience provides some justification for believing that pre-
market approval is less necessary.
The congestion claim might also seem permissible based on
FDA's willingness to accept generality as a mark of a
supplement claim. A claim for "maintaining clear nasal
function" is similar to the maintenance claims the FDA has
recognized. 1 1 Relying on generality as a factor permits a
measure of compromise under the FDA tests and permits a
wider recognition of structure and function claims. A claim for
temporary relief of "nasal stuffiness" would also seem to be a
supplement claim if the FDA were willing to view stuffiness as
due not solely to colds or other diseases, but related as well to
more general causes. How to deal with the classification of this
claim reflects choices on whether the determination turns on
traditional medical criteria (disease symptoms), the seriousness
of the effect in light of the consumer's ability to judge its effects,
or a test that considers claims stated in a more general way as
having non-disease functions. The tests vary in their ability to
permit compromise and adapt themselves to a more pragmatic
or conciliatory approach. 102  Which is appropriate involves
judgments about how important the health consequences are
and how important conciliation is on its own as a regulatory
goal.
An additional factor may also have played a role. The FDA
later announced plans to withdraw the use of
phenypropanolamine, an ingredient used in decongestant over-
the-counter drugs (OTC), for safety reasons, and the OTC drugs
were reformulated using another ingredient. 0 3  If the
decongestion claim had been recognized as an appropriate
supplement claim, it is possible there would have been a market
for herbal supplements making this claim. There would,
however, have been safety concerns if ephedrine was used in
101. See supra notes 55-56.
102. See Shapiro, supra note 8, and Freeman, supra note 9.
103. See FDA Talk Paper, FDA Issues Public Health Warning on
Phenylpropanolamine, Nov. 6, 2000 (available at
<fda.gov/bbs/topics/ANSWERS/ANS01051.html>), and Jeff Gerth & Sheryl Gay Stolberg,
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supplements to achieve the decongestion effect.. 10 4 Ephedrine
may also have a use in relieving congestion, since claims for
traditional Asian medicines include relief of cold symptoms. 0 5
Moreover, the FDA has proposed restricting use of ephedrine in
OTC drugs, at the request of the Drug Enforcement
Administration, because of its illicit use as a precursor in
making controlled substances like methamphetamine.106
Whether those factors played a role in the FDA's not allowing a
congestion claim for supplements is not clear, but these
considerations demonstrate choices regulators may sometimes
face.
D. Adequacy Of The Substantiation Model For Claims
Supplement claims are required to have substantiation, by
law, but no FDA prior approval of the claims is needed. 07 Thus,
DSHEA provides a test for whether substantiation is an
appropriate model for products which make a claim that would
ordinarily fall within the drug definition. Whether the
substantiation model can be sufficient if the claims truly are
non-disease claims relates to the criteria for substantiation
testing, and the means to enforce the requirement.
1. Enforcement Difficulties
To start with the last point, a major difficulty is that the
FDA has no express authority to obtain the records and studies
of food and supplement manufacturers. Without this authority,
the FDA has no routine way to check what studies the
manufacturers have done to substantiate their claims for
supplements. The FDA could try to seek access to the records
under its general authority to conduct "reasonable"
inspections. 08  When the FDA relied on this theory in a
rulemaking in the late 1960's, the Supreme Court found the
issue was not ripe until the FDA sought enforcement in a
specific context that permitted a judgment about the need for
104. See infra Part VII.B.3.
105. Dietary Supplements Containing Ephedrine Alkaloids, Proposed Rule, 62 Fed.
Reg. 30,677, 30,691 (1997) [hereinafter Proposed Ephedrine Rule].
106. Proposed Ephedrine Rule, 62 Fed. Reg. at 30,691.
107. 21 U.S.C. § 343(r)(6)(B) (1994).
108. 21 U.S.C. § 374 (1994). See also Herbal Remedies, supra note 1, at 695-96;
Commission Report, supra note 1, at 44 (author's individual views on need for FDA to
have access to files through administrative interpretation or legislation).
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the authority.10 9 To avoid the prolonged litigation that would
ensue if the FDA sought to obtain access to substantiation
records under its existing authority, Congress should give FDA
authority to obtain access to the records.
2. Substantiation Criteria
The substantiation model originated with the FTC's efforts
to regulate misleading advertising claims. An advertising claim
is considered misleading if the advertiser does not have
adequate substantiation for all objective claims before
disseminating the advertisement. 1 0 Thus, the maker of the
claim has the affirmative obligation to employ studies which are
adequate to support the claim. The use of substantiation for
these products is new, despite the FTC precedents, since there is
no separate FDA prior review of the claims on the label, and the
products are ingested, presenting more significant issues for
safety substantiation.
In determining what is adequate support, the FTC considers
what constitutes "competent and reliable scientific evidence" in
the overall context, including the amount of substantiation
experts in the field consider reasonable."' Determining the level
of substantiation needed involves a balancing test that calls for
consideration of the type of product, type of claim, the benefits of
a truthful statement, the ease of developing substantiation, the
consequences of a false claim and the amount of substantiation
the experts in the field believe is necessary. 112 The FTC would
accept significant scientific agreement as needed for
substantiation, when other agencies or authoritative bodies
recognize the standard, as in the case of health claims, but the
FTC does not expressly call for this level of support for other
109. Toilet Goods Ass'n v. Gardner, 387 U.S. 167 (1967).
110. FTC, Dietary Supplements: An Advertising Guide to the Industry,
<www.ftc.gov/bcp/conline/pubs/dietsupp.htm> [hereinafter Advertising Guide]. See
generally C. Lee Peeler & Susan Cohn, The Federal Trade Commission's Regulation of
Advertising Claims for Dietary Supplements, 50 FOOD & DRUG L. J. 349 (1995).
111. FTC Enforcement Policy Statement on Food Advertising, 59 Fed. Reg. 28,388,
28,393 (1994) [hereinafter FTC Enforcement Policy]; FTC Policy Statement on
Advertising Substantiation, 48 Fed. Reg. 10,471 (1984), reprinted in Thompson Medical
Co., 104 F.T.C. 648,839 (1984), affd, Thompson Medical Co. v. F.T.C., 791 F.2d 189 (D.C.
Cir. 1986), cert. denied. 479 U.S. 1086 (1987).
112. Advertising Guide, supra note 110, at 6 (substantiation will vary depending on
the product and claim, the consequences of a false claim and benefits of a truthful one,
the cost/feasibility of developing substantiation, and the amount of substantiation that
experts in the field believe reasonable). See also Commission Report, supra note 1, at 43.
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supplement claims. 113 Whether this level of support is needed is
affected by whether claims such as maintaining cardiovascular
function are viewed as claims that relate to matters of health
importance.
3. Application of Criteria to Supplement Claims
The FDA has stated that it agrees with the Commission's
report which made recommendations for substantiation after
considering the FTC's criteria." 4 How the criteria will apply
remains to be tested in particular cases involving the new types
of labeling claims for supplements. Since the claims recognized
by the FDA as permissible supplement claims vary in their
health importance, with some relating to minor matters, like
hair loss, the need to have significant scientific agreement to
support claims would seem to vary.
Another concern is the extent to which public disclosure of
the substantiation data is needed in order to make it available
to the wider medical and scientific community. The public
availability permits independent scientific evaluation of the
supporting material." 5 Moreover, public availability provides a
way for doctors to know more about the basis for claims and to
be in a better position to advise patients.
Some supplement manufacturers may regard the testing
and data relied on for substantiation to be proprietary and trade
secrets. If they do, it increases the importance of the FDA
having access to the test records. Some general summary of the
type of test results used for substantiation should still be made
publicly available. 16 Moreover, when the data is not fully
available, experts may find the claim to be adequately supported
113. FTC Enforcement Policy Statement on Food Advertising, 59 Fed. Reg. 28,388,
at 28,393 ("principal guide" for the support for advertisements for health claims);
Advertising Guide, supra note 110, at 6-7. See also Herbal Remedies, supra note 1, at 694
(that significant scientific agreement should be needed for claims of health importance).
114. Final Claims Rule, 65 Fed. Reg. 999, 1032 (2000), (citing Notice, 63 Fed. Reg.
23,624, at 23,633 (1998)). See Commission Report, supra note 1, at 43. See infra note 131
(FDA's criteria for significant agreement to support health claims).
115. FDA has stated that it "would expect" a manufacturer to provide those who
request copies of the substantiation data contrary and supporting studies. FDA Final
Claims Rule, 65 Fed. Reg. at 1032.
116. The FTC will consider unpublished proprietary studies in connection with the
substantiation of claims, but recognizes that publication in a peer-reviewed journal
provides some measure of scrutiny. Advertising Guide, supra note 110, at 9. While the
test data for new drugs is confidential, FDA has developed policies to release summaries
of the basis for approval. See 21 C.F.R. § 314.430(e)(2) (2000); Hurr & MERRILL, FOOD
AND DRUG LAW 531 (1991); 39 Fed. Reg. 44,602, at 44,635-36 (1974).
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only if the claim has been subject to an in-depth independent
evaluation by expert review panels with strong credentials.
The difficulty in doing studies is a factor under the FTC's
criteria. 117 This factor has the most pertinence when the claim
relates to prevention and the support necessitates long-term
studies. The issue also arises for health claims, and the
discussion below explores if there are ways to permit
preliminary claims in a way that provides an incentive for
needed research. 118
E. Is There A Need for Substantiation of Supplement Claims?
On a policy basis, some may question the need for any
substantiation requirement for supplement claims, and
concomitantly the need for rigorous enforcement. If supplement
claims deal with non-diseases and nonserious conditions within
the ability of the consumer to evaluate, is there any real need to
have the government heavily involved in reviewing how much
testing supports the claim? If, for example, a supplement claims
to reduce hair loss but it does not produce, won't consumers
realize this, therefore the product fails in the marketplace? If a
supplement is safe but makes vague claims, does it matter
whether the claim is proven?
Supplement claims vary under the FDA rule, and some are
harder for consumers to evaluate than others. The
absentminded, for example, may have special difficulty in
knowing whether the product works. Furthermore, can
consumers know whether a product helps maintain the immune
system or the cardiovascular system? Those suffering from hair
loss may let their hopes for improvement cloud their judgment
while they spend time and money on the product. Allowing false
or unproven claims to be made routinely on commercial
products, as a matter of policy, breeds distrust and cynicism
about the commercial market.
The consumer's ability to judge the results, while it does not
eliminate the need for regulation, has an important relevance to
117. See supra note 88.
118. See infra Part IV.D. The FTC weighs the cost and feasibility of studies against
the other factors to ensure that the valuable product information is not withheld from
consumers because the cost of developing substantiation is prohibitive. Advertising
Guide, supra note 110, at 6. An advertiser cannot "make any claim it wishes simply
because the cost of research is too high." See also Commission Report, supra note 1, at 70
(difficulties of long-term studies), and 69 '(need for placebo studies and challenges for
claims such as those for enhancing well being or the immune function).
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the priorities for enforcement. The FDA's enforcement efforts
sensibly should be focused first on safety, and next on claims
beyond ready consumer evaluation. Effects which consumers
can assess need less attention, but should still be subject to the
possibility of enforcement action when circumstances warrant,
especially for claims with complete lack of support.
The claims for supplements also indirectly affect their
safety. The claims induce consumer use. If the product has no
usefulness it needlessly leads consumers to be exposed to
whatever risk the product has. While this may be considered to
be solely a safety matter, the FDA views the safety and efficacy
issues as interconnected in a risk-benefit determination of
safety.119
The lack of effectiveness may affect the priority for
enforcement action, as a way of forestalling needless risks, even
if the safety risks are unknown or not well-documented.
IV. DISCLOSURE MODEL: HEALTH CLAIMS AND COMMERCIAL
FREE SPEECH
A. Judicial Determination on Health Claims
1. Constitutional Basis for Disclosures
A different regulatory model, based on disclosures, has
recently received acceptance in a court decision relating to
supplements on constitutional grounds based on commercial free
speech. Under this approach, Congress cannot "suppress"
claims by requiring studies or scientific acceptance, but must
instead allow the claim with disclosures qualifying it, unless
there is a showing that such disclosures would be insufficient to
prevent consumers from being misled. The Court of Appeals for
the District of Columbia Circuit applied this "preference for
disclosure over outright suppression" to health claims for dietary
supplements in Pearson v. Shalala.120
Health claims are claims for foods, about diet-related
disease factors, such as the claims on breakfast cereals for the
usefulness of fiber in relationship to heart disease.' 2' By law,
119. See Final Claims Rule, 65 Fed. Reg. at 1003; see also infra Part VI.B.3.b.
120. 164 F.3d 650, 657 (D.C. Cir. 1999) (rejecting the government's argument and
relying on Bates v. State Bar of Arizona, 433 U.S. 350 (1977)).
121. 21 U.S.C. § 343(r)(1) (1994); 21 C.F.R. § 101.81 (2000) (soluble fiber and
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disease claims for foods can be made only with FDA approval,
based on publicly available evidence and significant scientific
agreement. 122 While Congress gave the FDA the discretion to
determine the tests and procedures to be applied to health
claims for supplements, the FDA decided to use the same tests
as those statutorily applicable to foods.123
In Pearson, the supplements sought to make claims based
on preliminary studies performed solely on foods. The court
thought the FDA could not preclude the claims since the
potential for deception could be dealt with by disclosures about
the inconclusiveness of the studies and lack of agency
approval. 124 The court remanded to the FDA to determine what
specific disclaimers are needed to prevent deception. A claim
may be barred if it is against the weight of the evidence and
disclaimers would be confusing. The FDA could also seek to
show consumers would be bewildered by disclaimers about the
inconclusiveness of the supporting studies, but the court
believed that the FDA would have to have "empirical evidence"
that consumers would be confused. 125 On remand, the agency
also has to provide better criteria for what constitutes
"significant scientific agreement."126
2. Role of Significant Scientific Agreement
Health claims involve long-term effects in preventing
diseases. Whether the effect occurs may not be determinable
from controlled studies, for ethical and practical reasons, and
may depend instead on the results of large-scale epidemiological
studies or other evidence. 127 Epidemiological studies are often
expensive and complex to interpret. In assessing claims in this
context, experts rely on the strength, consistency and
preponderance of data, and the degree of concordance of the
evidence. 128 Having significant scientific agreement to support
coronary heart disease).
122. 21 U.S.C. §§ 321(g)(1), 343(r)(1)(B) & 343(r)(3)(B) (1994).
123. 21 U.S.C. § 343(r)(5)(D) (1994) (FDA can determine the 'procedure and
standard" for claims on nutritional supplements).
124. Pearson v. Shalala, 164 F.3d 650, 657 (D.C. Cir. 1999).
125. Id. at 659
126. Id. at 660-61.
127. Commission Report, supra note 1, at 31.
128. Committee on Diet and Health, Nat'l Research Council, Diet and Health:
Implications for Reducing Chronic Disease Risk 5 (1989); Commission Report, supra note
1, at 31 vii and 35 (standard is appropriate and serves the public interest); Peeler &
Cohen, supra note 110 (significant scientific agreement as principal guide for
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the claim provides a high standard of evidence for claims that
promote the public health and that have health importance.
The FDA's guidance for significant scientific agreement
indicates it is met "when the validity of the relationship is not
likely to be reversed by new evolving science.' 1 29
3. Remands, Disclaimers and the Lack of Scientific Agreement
On remand, the FDA adopted an "interim enforcement
policy" pending consumer research and reconsideration of the
general health claims regulation. 130 Under this policy, the FDA
will not take enforcement action against supplement claims for
which there is no significant scientific agreement if the claim is
supported by the weight of the evidence and the claim can be
qualified in a non-misleading way.131
Under the interim enforcement policy, when claims are
permitted, no disclaimer is needed about the lack of significant
scientific agreement. An illustration of the qualifying language
FDA considers sufficient is provided by the agency's policy
toward supplement claims for omega-3 fatty acids. 132 The claim
is to indicate that the studies on fish, while suggestive, are not
conclusive, and that it is not known what effects the supplement
"may or may not have" on the risks of coronary heart disease in
the general population. While this qualifying language helps
consumers, a disclaimer that the claim is not supported by
significant scientific agreement (once the criteria is established)
is better because it alerts consumers to the type of support that
is missing. 33
advertisement of health claims under FTC's substantiation criteria in light of health
importance of claims).
129. Guidance for Industry Significant Scientific Agreement in the Review of Health
Claims for Conventional Foods and Dietary Supplements, page 16, (visited Dec. 22,
1999) <http://vm.cfsan.fda.gov/-dms/ssaguide.html>. While significant agreement does
not require "consensus in the sense of unanimity," or an "arbitrary quantitative criteria,"
it "represents more than an initial body of emerging evidence." The information relating
to the claim needs to be available to the scientific community.
130. Notice, Food Labeling; Health Claims and Label Statements; Update to
Strategy for Implementation of the Pearson Court Decision, 65 Fed. Reg. 59,855, 59,857
(Oct. 6, 2000).
131. Id. at 59,856.
132. Letter Regarding Dietary Supplement Health Claims for Omega-3 Fatty Acids
and Coronary Heart Disease to Jonathan W. Emord, Esq., Oct. 31, 2000, available at
<httpJ/vm.cfsan.fda.gov/dms/ds-ltrll.html>.
133. Constitutionalizing, supra note 4, at 849, 851. Dietary Supplement Health and
Education Act: Is the FDA Trying to Change the Intent of Congress? Hearings Before the
House Comm. On Gov't Reform, 106th Cong. (1999)
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The FDA recently took another approach by requiring
that a disclaimer for folic acid claims state that "FDA does not
endorse this claim," along with a succinct statement of the
reasons. 134 This type of disclaimer makes it clear for consumers
how a claim lacks the support an expert agency considers
needed.
4. Research Incentives and Preliminary Claims: Considering
Alternative Non-Constitutional Grounds
Congress gave the FDA discretion to determine the
standards for health claims on supplements. 135 This delegation
to the agency offered a way to resolve the issues without having
to reach the constitutional issues. 36 In addition, this delegation
allows the agency to consider whether there are ever
circumstances which could justify allowing preliminary health
claims. These circumstances can encompass the difficulties of
doing long-term studies, and the need to provide research
incentives.137
One of the criteria which affects the testing needed to
substantiate claims is the difficulty of doing studies. Long-term
epidemiological studies to support health claims are particularly
difficult and expensive. Supplement manufacturers also report
they have difficulty in protecting their research investment
because claims for a generic product are difficult to patent. 38
These factors do not, though, eliminate the need for a
disclaimer about the lack of scientific support for preliminary
claims, but they may make it appropriate to permit labeling
claims that an acceptable research program is being undertaken
to determine whether the preliminary claims can be
<httpJ/www.house.gov/reformlhearings/healthcaresupplementn325 99/Gilhooley.htm>
134. Letter Regarding a Health Claim for Folic Acid and Neural Tube Defects to
Jonathan W. Emord, Esq., April 3, 2001 (available at <http://cfsan.fda.govrdms/ds-
ltr22.html>). The agency developed the disclaimer on remand from a District Court
decision that FDA was incorrect in placing on the marketer the burden to show that a
claim was supported by the weight of the evidence, and that once credible evidence exists
for a claim, it should be allowed with disclaimers. Pearson v. Shalala, 2001 U.S. Dist.
LEXIS 1253 (D. D.C. 2001)
135. 21 U.S.C. § 343(r)(5)(D) (1994).
136. Constitutionalizing, supra note 4, at 858.
137. KEYSTONE CENTER, The Keystone National Policy Dialogue on Food, Nutrition
and Health 77-84 (1996) (means for providing research incentives for foods and generic
products include exclusivity, and royalties as well as increases public and private
funding). See also Herbal Remedies, supra note 1, at 714-15.
138. Commission Report, supra note 1, at 69; Constitutionalizing, supra note 4, at
855, n. 211 and 214.
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scientifically established. Approval of a "research-in-progress"
claim could encourage manufacturers to undertake, individually
or cooperatively, research programs eligible for the claim.139
The FDA would need to identify the criteria for what makes
a research program acceptable. The FDA might allow the claim
only if scientists believe the preliminary claim is probably valid.
The label should also indicate the expected duration of the
research program to provide some impetus to finish the
research. Such a program is an alternative to having a research
limbo of preliminary claims which never get further tested.
B. Applicability of Disclosure Model to Other Supplement Claims
The Pearson decision has created uncertainty about
whether there are other areas of food and drug regulation that
are now constitutionally beyond Congressional control when the
manufacturer provides disclaimers instead of meeting the
statutory requirements. Arguably, for example, Congress could
not require substantiation for structure and function claims on
supplements. 140 Instead, manufacturers might claim they need
only make a disclosure that the claim is based on inconclusive
studies unless the FDA can show the claim is against the weight
of the evidence. To be adequate, though, at a minimum, such a
disclosure should indicate there is a lack of adequate scientific
substantiation.
Some comments on FDA's recent rule even maintained,
based on Pearson, the First Amendment permits express disease
claims to be made for supplements when accompanied by non-
misleading disclosures about the basis for the claim and lack of
FDA approval. The FDA rejected that comment, and pointed
out:
If companies could avoid the time and expense of complying with the new drug
provisions of the act merely by attaching a disclaimer to a disease treatment or
prevention claim, the long-standing system of drug regulation in this country
would be eviscerated, with serious public health consequences.
14 1
The Pearson court also stated that drugs "appear to be in an
entirely different category-the potential for harm presumably
139. See Constitutionalizing, supra note 4, at 854-57, n. 218, for a discussion of such
a program based on legislative, and possibly administrative, grounds. The alternative of
simply disclosing whether the manufacturer or others are conducting any tests is not as
satisfactory, especially for claims that have health importance or that are beyond
consumer assessment.
140. 21 U.S.C. § 343(r)(6) (1994). See also infra Part III.D.
141. Final Claims Rule, 65 Fed. Reg. 999, 1040 (2000).
114 Vol. 62
30
Montana Law Review, Vol. 62 [2001], Iss. 1, Art. 3
https://scholarship.law.umt.edu/mlr/vol62/iss1/3
DIETARY SUPPLEMENTS
is much greater.'1 42 This distinction in risk of harm is strongest
for prescription drugs and claims that would divert consumers
from more effective treatment for a serious condition. 143
A different question arises, though, if supplements are safe
and claim to treat diseases in a way that does not pose serious
harm, such as by treating mild disease conditions like those
treated by OTC drugs for relief from fever. If commercial free
speech permits claims to be made for mild disease conditions,
with disclaimers, the claims for supplements would be expanded
beyond the limits of the scope permitted by Congress in DSHEA.
Whether the courts would go this far is uncertain, as well as
what would be considered a claim for a mild and non-harmful
condition. Would claims to prevent colds or treat arthritis be
protected? The disclaimers needed and the means to ensure
that the products are safe are important questions given this
possible expansion on constitutional grounds of the opportunity
for claims for supplements and other products.
V. TRADITIONAL MEDICINES AND A DISCLOSURE MODEL
A. Policy Proposal for Traditional Medicines
What constitutes adequate disclaimers for disease claims on
supplements is a policy issue that the Commission extensively
discussed. This discussion indicates the difficult issues involved
and the importance of the type of disclaimers. Similar issues
would also arise if the courts were to consider recognizing
disease claims for mild conditions as constitutionally protected
under commercial free speech.
Most Commission members believed supplements should be
able to make express disease claims about their traditional uses,
provided there was other support and the label bore a disclaimer
that the support is based on traditional use. They believed this
would be better and less confusing than the system created by
DSHEA under which dietary supplements are sold with
142. Pearson v. Shalala, 164 F.3d 650, 656, n. 6 (D.C. Cir. 1999).
143. While the Pearson court considered drugs to be different, there has been
inconclusive litigation on whether commercial free speech protects the promotion of new
claims for prescription drugs by manufacturers to doctors through the distribution of
medical journal reprints and continuing medical education programs. See Washington
Legal Foundation v. Henney, 202 F.3d 331 (D.C.Cir. 2000), dismissing the appeal from
Washington Legal Foundation v. Henney, 56 F. Supp. 2d 81 (D.D.C. 1999), and
Constitutionalizing, supra note 4, at 815-44.
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structure and function claims which can indirectly suggest
disease use to consumers, and which "may also create a climate
of deception that serves neither the industry nor consumers."144
B. Disclaimers Needed and Scientific Standards
The Commission agreed that this approach deserved more
study as a policy matter in light of international models.
However, in my view, a disclaimer is not adequate if it merely
says the support is based on use as a traditional medicine.
Instead, if disease claims are to be made, the disclosure should
say "not based on adequate and well-controlled studies and not
generally recognized as effective."145  This approach to
disclaimers is like the one suggested earlier: the disclaimer
needs to clearly state whether or not the claim is based on
scientific testing and standards. 46 Whatever role tradition may
have in identifying potential effective ingredients, scientific
testing is needed to have reliable proof. The effort to regulate
disclosures tests whether science and medical expertise sets the
standard for what makes a claim reliable and what the
consumer needs to know.
If disease claims are to be allowed on scientifically unproven
"safe" products or supplements, it should not be on the basis
that they really work, but that the consumer should have the
freedom-of-choice to use even unproven products when
consumers are adequately informed of the choice being made.' 47
This requires clear disclosures. The directness and bluntness of
disclosures, if adequate, may lessen the appeal of making these
claims.
C. Dietary Supplements and Freedom of Choice
Dietary supplements have become the way in practice to
144. Commission Report, supra note 1, at 55-56.
145. Id. at 52-54; Herbal Remedies, supra note 1, at 709-22.
146. See infra Parts III.C.3.d, IV.A.3.
147. Herbal Remedies, supra note 1, at 715-22. See also J. Richard Crout, The
Nature of Regulatory Choices, 33 FOOD DRUG COsM. L. J. 413, 422 (1978) (stating:
The drug regulatory laws deal with science and to risk its essential features in
the political arena over relatively innocuous product is to court a serious long-
term setback in the rational control of powerful chemicals in our
society... [Tihe choice is between competing good values-do we want scientific
rationality or personal freedom? And if we want the latter, are we willing to
pay the price of a few frauds here and there?)
See also Herbal Remedies, supra note 1, at 716, 719-21.
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provide consumers with the opportunity to choose a product
which may be used for disease purposes without the type of
scientific testing needed for approval of claims. DSHEA allows
non-food products to be sold as supplements, and the
supplement claim may indirectly suggest these broader uses.
While imperfect, DSHEA may continue to have this indirect role
of providing choice to consumers on an off-label basis about
unproven disease uses. While other approaches may be better,
it is doubtful that there would be agreement on the disclaimers
needed or the willingness of Congress to permit disease claims
based on disclaimers 48
VI. SAFETY OF SUPPLEMENTS
A. Changes Made By DSHEA's Safety Standard
Whether the safety of supplements under the deregulatory
scheme established by DSHEA provides adequate means to
protect consumers from unsafe products needs evaluation.
Consumers experiment with the new uses of dietary
supplements because consumers assume they are safe. The
"dietary" designation may lead consumers to believe the
supplements are as safe as foods.
Dietary supplements are not, though, subject to any pre-
market approval for safety. DSHEA exempted supplements
from being considered "food additives."1 49 The food additive
provisions ordinarily necessitate FDA approval of the safety of
substances added to foods, unless the substance is generally
recognized by experts as safe based on scientific testing or use in
food before the adoption of the statute in 1958.150 Before
DSHEA, judicial decisions had narrowed the applicability of the
food additive provisions by the finding that single ingredient
supplements sold in gelcap form were not food additives and
were subject only to the requirements governing non-added
foods. 151 However, the judicial decisions were made at a time
when supplements had to be foods in a nutritional sense. The
exemption in DSHEA from the food additive requirements
includes herbal supplements with no nutritional value or history
148. See Herbal Remedies, supra note 1, at 721-24.
149. 21 U.S.C. § 321(s)(6) (1994).
150. 21 U.S.C. §§ 321(s), 348 (1994).
151. United States v. 29 Cartons of an Article of Food, 987 F.2d 33 (1st Cir. 1993);
United States v. Viponte Ltd. Black Currant Oil, 984 F.2d 814 (7th Cir. 1993).
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of use in food, a far broader category.
Under DSHEA, the FDA has the burden of showing that a
supplement poses "significant or unreasonable risk" under the
doses stated on the label before use can be limited. 152 The test is
similar to the one that applied to foods under the first FDA Act
passed in 1906, at the turn of the last century.153 Now, though,
the FDA can use rulemaking as well as court proceedings to
enforce the provision. 5 4
B. Need for Safety Substantiation Requirement
1. Drawbacks of DSHEA Safety Provisions
An important problem with supplements is the unknown.
According to the FDA, the safety and benefits of "many"
supplements has not been proven by adequate testing. 55 There
also have been a number of reports of adverse reactions from
supplements. 56 Some relate to contamination with drugs or
heavy metals. 157  Some involve interactions with drugs,
including the possible interaction of St. John's Wort with
anesthesia used for surgery 58 Some involve quality control
problems. 59 Confusion about the name of a Chinese herb led to
152. 21 U.S.C. § 342(f) (1994).
153. 21 U.S.C. § 342(a) (adding that substances in foods violate the law if the
substance "may render [the food] injurious to health"). The Supreme Court interpreted
the standard as not applying if the substance "cannot by any possibility, when the facts
are reasonably considered, injure the health of any consumer." United States v.
Lexington Mill Co., 232 U.S. 399, 411 (1914).
154. 21 U.S.C. § 371(a) (1994). This provision was recognized as giving the agency
the authority to issue substantive rules in National Nutritional Foods Ass'n v.
Weinberger, 512 F.2d 688 (2d Cir. 1975).
155. Final Claims Rule, 65 Fed. Reg 999, 1003 (2000). See also Laurie Tarkan,
Natural Remedies for Menopause Gain Popularity, But Self-Treatment to Alternatives to
Hormone Replacement Therapy carries Risk, Experts Warn, N. Y. TIMES, June 20, 2000,
at F7.
156. M. Angell & J.P. Kassirer, Alternative Medicines-The Risks of Untested and
Unregulated Remedies, 339 NEW ENG. J. MED. 839 (1998).
157. Guy Gugliotta, Health Concerns over Herbal Aids; As Industry Booms, Analysis
Suggests Rising Toll in Illness and Death, WASHINGTON POST, March 19, 2000, at A 01
(reporting its own "first national survey" including reports from poison control centers,
and findings by California investigators in '1998 that one-third of imported Asian
herbals were "spiked with drugs not listed on the label or contained lead, arsenic or
mercury.") (Heavy metals may be viewed as beneficial in traditional medicines).
158. Eric Nagourney, A Warning Not to Mix Surgery and Herbs, N.Y. TIMES, July 6,
1999, at F5.
159. FDA has the express authority to establish good manufacturing practices for
supplements, and these rules could provide an alternative way to deal with some safety-
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a manufacturing error and the inadvertent use in a weight loss
supplement of a different herb which not only caused renal
failure but also cancer.160
2. Safety Substantiation as Preferable to DSHEA
A major weakness in DSHEA is that it does not impose on
all dietary supplements the burden and obligation to
affirmatively substantiate their safety. DSHEA imposes a
requirement for safety substantiation, but limits it to new
ingredients sold after 1994, and defines "new" in a narrow way
to exclude "any" dietary ingredient marketed before DSHEA,
apparently even if for a different use. 161 While not without
ambiguity, no substantiation seems required when new claims
are made. All the supplements, whether sold before or after
1994, should have to substantiate their safety. 162
If manufacturers had to substantiate safety, they would
have to perform tests, in accordance with scientific standards, to
determine risks and establish a safe level. They would have a
responsibility to follow-up on adverse reaction reports, and
undertake whatever testing or changes scientists would consider
necessary to assure safety.
Because of the health importance of safety risks, significant
scientific approval is also relevant in determining whether the
product has been substantiated. 163 There may be times, though,
in which a process of a publicly disclosed independent evaluation
of the testing by highly qualified experts could be viewed as
tantamount to scientific acceptance. A proxy system needs
consideration because there can be difficulties in achieving
actual scientific acceptance when new adverse reactions occur,
or if peer-reviewed journals do not publish studies for these
products. 1
related problems. 21 U.S.C. § 342(g)(2) (1994).
160. J.L. Nortier et al., Urothelial Carcinoma Associated with the Use of a Chinese
Herb, 342 NEW ENG. J. MED. 1686 (2000).
161. 21 U.S.C. § 350(b) (1994). Perhaps when the level of use recommended has
changed significantly, the supplement might be considered new, but this is debatable.
Herbal Remedies, supra note 1, at 704.
162. The Report of the FDLI Futurist Task Force on Dietary Supplements projected
that it is "not unlikely" that the law may be amended to impose some additional safety-
related requirements for supplements, which might take the form of an obligation to
substantiate safety. 55 FOOD & DRUG L.J. 17, (2000).
163. See criteria for safety substantiation in Part III.D.2.
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3. Ephedrine, Weight Control and Safety Determinations in
Practice
a. Effort Needed to Regulate
Under the present safety provisions of the DSHEA, the
difficulty and resource burdens of regulating supplements is
demonstrated by the FDA's inconclusive effort to limit the
amount of ephedrine in supplements. This effort also is a case-
study of some issues which can arise in determining the safety of
supplements, no matter what model of safety regulation is used,
including how to identify the use, how to deal with overuse, how
to make warnings adequate and how to determine acceptable
risk.
The proposed rule took 55 pages in the Federal Register,
and identified 800 adverse events, and some deaths, associated
with supplements containing ephedrine. These reports
amounted to half of all adverse reactions reported for all forms
of supplements. 165  Ephedrine is an "amphetamine-like
compound." 166 The proposal limited the levels of ephedrine in
individual doses, the length of use to no more than 7 days, and
provided for warnings that exceeding the limits "may cause
heart attack, stroke, seizure or death."167
The proposal would have allowed claims for short-term use
such as for alertness or increased energy. 168 However, the
proposal precluded any claim for weight loss, because weight
loss cannot be safely or effectively achieved in a short period of
time, and use beyond seven days posed unreasonable risks.169
The proposal thus viewed any weight loss claim as one implicitly
for an intended use for a long period that created risks, rather
than as a matter of misuse by the consumer in excess of the
labeling instructions. Under the DSHEA, safety is determined
based on the dose levels "recommended or suggested in the
labeling. ",170
Before the election, the FDA partially withdrew its proposal
165. Proposed Ephedrine Rule, 62 Fed. Reg. 30,677, 30,678 (1997).
166. Proposed Ephedrine Rule, 62 Fed. Reg. at 30,678. See infra note 87 for
concerns about diversion of OTC ephedrine products. The ephedrine in some weight
control products is claimed by the manufacturer not to be susceptible to diversion.
167. Proposed Ephedrine Rule, 62 Fed. Reg. at 17,476.
168. Id. at 30,718. 21 C.F.R. § 111.100(f)(1).
169. Proposed Ephedrine Rule, 62 Fed. Reg. at 30,697.
170. 21 U.S.C. § 342(f) (1994).
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to limit ephedrine use, pending further consideration in light of
a recommendation by the General Accounting Office that the
FDA "provide stronger evidence" for the proposal and greater
"transparency" in its cost-benefit analysis. 171  The FDA is
considering information on 270 additional adverse events not
known at the time of the proposal and has invited public
comment on whether the proposed limits or alternatives are
needed. 172  The effect of the FDA's re-consideration of the
proposal is to leave the issue of how to regulate ephedrine to the
new Administration.
b. Determining Safety: Risk /Benefits, and Acceptable Risks
One alternative which may be raised is whether use for
ordinary weight loss claims can be considered safe under some
conditions that limit the length and amount of use. 73 In an
effort to understand the choices regulators face, one might
hypothetically consider whether the permissible dose could be
reduced to a quarter of the amount to allow use for a month for
ordinary minor weight reduction. If any weight loss claims are
allowed for ephedrine products, however, there remains a risk
consumers will exceed the label limits. That risk is greater, if,
as is often the case, increasing the dose increases effectiveness,
but also the risks.
The FDA's authority with respect to safety is based on the
"conditions of use recommended or suggested" in the labeling. 74
When the agency's authority is restricted to claims about
intended uses, the labeling needs to be especially clear about the
use intended and the consequences of overuse. 75 Furthermore,
171. Dietary Supplements Containing Ephedrine Alkaloids; Withdrawal in Part, 65
Fed. Reg. 17,474, at 17,475 (2000) (proposed Apr. 3, 2000) [hereinafter Ephedrine Rule
Withdrawal].
172. Id. See also 65 Fed. Reg. 17509 (2000) (providing for availability of additional
adverse reaction reports).
173. The FDA's proposed and final rule on supplement claims recognizes that
supplements can claim to be for ordinary weight loss, since that condition is different
from treating obesity, and is not itself a disease. Final Claims Rule, 65 Fed. Reg. 999,
1027 (2000). The use of ephedrine for weight loss may expand because of FDA's plans to
propose the withdrawal use of phenylpropanolamine (PPA) in over-the-counter drugs
because of risk of stroke. While OTC marketers are switching to pseudoephedrine as a
replacement for PPA in OTC decongestants, there is no alternative OTC ingredient for
use as an appetite suppressant, and manufacturers may market the product using the
herbal ephedrine. See Jeff Gerth & Sheryl Gay Stolberg, Another Part of the Battle:
Keeping Drugs on the Shelves of Stores, N.Y. TIMEs, Dec. 13, 2000, at 31.
174. 21 U.S.C. § 342(f) (1994).
175. The type of labeling to alert consumers about risks can be regulated by the
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as the ephedrine proposal illustrated, the use of the supplement
can be identified in a way that attributes the risk to the
intended use rather than to overuse. The possibility of
redefining and limiting the claim to make the use safe, if the
limits are observed, also illustrates the tension between claims
and misuses, and the opportunities for compromise and
pragmatic judgments under DSHEA that some may bemoan and
some may accept.
To pursue the analysis of a possible dosage reduction, if the
product poses significant risks for ordinary limited weight loss,
even when used at one-quarter of the dose or other restrictions,
it should not be permitted. Such a product should be viewed as
posing a significant risk not permissible under DSHEA. 176 The
adequacy of the risk information and scientific evaluations, in
light of the comments, will be key in making that determination.
The effectiveness of the product in achieving its claimed effects
on a limited basis also has relevance. If the effectiveness of the
claim cannot be substantiated, there is a separate reason for
precluding it. 177 Whether to allow time for additional studies to
substantiate its effectiveness with the dose restrictions also
needs to be considered.
In addition, the FDA has stated that the safety of
supplements has to be determined on a risk-benefit basis in
light of the health benefits claimed. 178 This type of risk-benefit
balancing is used for determining drug safety, but is not
typically used for foods, nor, until now, for supplements. As a
result, there is an interconnection between the substantiation of
the effectiveness of supplements and the determination of the
acceptability of the risks it poses. If the product is ineffective for
limited weight loss under its labeling restrictions, its
ineffectiveness may also tempt users to exceed the dose
restrictions and incur greater risks that are unreasonably high.
The acceptable level of risk from the intended dose raises a
different issue. The appropriate benchmark test for determining
acceptable risk would seem to be the scale of risks associated
with OTC drugs. This approach would seem to lead to
permitting only fairly limited risks in the interest of furthering
consumer safety.
FDA based on its authority to prevent deceptive labeling. 21 U.S.C. § 343(a)(1) (1994).
176. 21 U.S.C. § 342(f) (1994).
177. 21 U.S.C. § 343(r)(6) (1994) (substantiation requirement).
178. Final Claims Rule, 65 Fed. Reg. at 1003.
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c. Risks from Misuse: Labeling and Distribution Limits
When prescription drugs pose risks, the matter is typically
dealt with by providing additional warnings to physicians that
limit the use of the drug, and redefine the approved and
appropriate use of the drug.179
Supplements are used by ordinary consumers, though, and
when overuse poses serious risks, the label needs to identify
clearly to lay users the parameters of the appropriate use, and
the dangers of exceeding these limits. The FDA-proposed
warning for ephedrine seems blunt, referring as it does to risks
of "heart attack, stroke, seizure, or death."180 Still, to ensure
consumer awareness, the warning may need to be a boxed
warning, like those used in prescription drug labeling for serious
warnings. This type of prominence would seem especially
necessary if any type of weight loss claim were to be allowed
because of the risk that the label restrictions will be exceeded to
enhance the effects.
More study is also needed on ways to make information on
the labeling about risks more real and understandable for lay
users. The labeling may need to convey information to
consumers about risk factors associated with increased risk.181
Perhaps, package inserts should provide real-life examples of
the harm suffered by typical users (without names) who used
the product at doses in excess of the labeling. The FDA proposed
rule provided reports of harm to individuals from the use of
ephedrine in various products. 8 2
Finally, if the revised labeling and warnings are insufficient
to prevent a widespread overuse of a product that causes a
substantial number of deaths and serious harm, other measures
may need to be considered, including possible limits on
distribution. Perhaps users should be required to consult a
physician before using supplements for a purpose which leads to
wide, harmful overuse. The advice from physicians can make
consumers better able to understand the risks and intended use,
and help ensure there is a medical justification for exposure to
greater risks.
Whether the FDA could impose such limits under the
179. See 21 CFR § 201.57(e) (2001) (requiring label revisions "as soon as there is
reasonable evidence of an association of a serious hazard" with the drug).
180. Proposed Ephedrine Rule, 62 Fed. Reg. at 30,718.
181. Id. at 30,687, 30,692.
182. Id. at 30,718-24.
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existing law is uncertain. The FDA's effort to restrict the
distribution of prescription drugs to prevent harm when
physicians failed to comply with labeling restrictions has been
judicially rejected. 8 3 Removal of a drug to prevent risks has
been upheld, though, notwithstanding there may have been
some safe uses for which the drug could have been labeled. 8 4
The FDA has also conditioned approval of drugs on distribution
limits, based on the manufacturer's voluntary acceptance of the
restrictions, or the approval of the drug on an expedited basis. 8 5
Thus, the FDA might seek to have the manufacturer accept
voluntary limits on the distribution of supplements. The agency
might also test whether distribution limits can be required to
make a product sold to consumers safe with respect to risks of
overuse which foreseeably occur under the suggested labeling.
This position has added strength when consumers are using the
product for the use indicated on the labeling but regularly
exceed the stated dose.'8 6
4. Need for Legislative Action
a. Authority, Inspections and Adverse Reaction Reporting
The FDA could use the existing law to induce manufacturers
indirectly to substantiate the safety of all supplements, by
requiring a warning if there is inadequate substantiation of the
safety 187 Legislative action to require safety substantiation for
183. American Pharm. Assoc. v. Weinberger, 377 F. Supp 824 (D.D.C. 1974), aff'd
sub nom American Pharm. Ass'n v. Mathews, 530 F.2d 1054 (D.C. Cir. 1976) (per
curiam).
184. Forsham v. Califano, 442 F. Supp 203 (D.D.C. 1977).
185. Margaret Gilhooley, When Drugs Are Safe for Some Uses But Not Others: The
FDA Experience and Alternatives for Products Liability, 36 HOuS. L. REV. 927-45 (1999).
186. In the 1950's, the FDA was able to require that certain drugs be sold only by
prescription based on the requirement that drugs bear adequate directions for use.
United States v. El-O-Pathic Pharmacy, 192 F.2d 62 (9th Cir. 1951) (citing 21 U.S.C. §
352(f) (1994)). The agency found consumers could not understand the proper safe use
without medical advice, but there may also have been a concern about protecting
consumers from misuse of the products, contrary to the labeling, given that the product
at issue was testosterone. Id. at 65. The approach suggested here is similar in not being
based on a specific statutory authority to limit distribution or require a prescription, and
in having a similar rationale that the products are not safe, as labeled, without the
additional advice provided by physicians. If the FDA does not have the authority under
the existing law to impose additional limits to prevent substantial harm in this setting,
change in the law may need to be considered.
187. The warning would be based on the authority to prevent deceptive claims and
omissions. 21 U.S.C. §§ 321(n), 343(a) (1994). Based on similar authority, FDA has
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all supplements is preferable, though, because the obligation
would be direct and the legislation can provide for inspection of
records, and other measures to ensure that manufacturers meet
their obligation to determine the safety of supplements. These
measures also include having a better system for determining
adverse reactions from supplements, and a system for
registration or identification of establishments making
supplements.188
b. Resources and a Substantiation Assurance Fee
Congress also needs to provide adequate resources to the agency
to monitor substantiation. Congress should require those who
market dietary supplements to pay a "substantiation assurance
fee." When there is no pre-market approval, the government
has to determine whether products are safe and whether the
claims have been substantiated after the products are marketed.
This fee would cover the government's extra costs for monitoring
the safety and efficacy of supplements.
To ensure monitoring of the appropriate level for the fee, the
authorization for the fee should have a five-year life, like that
for user fees for new drugs. 8 9  Moreover, some type of
independent survey should be done to determine the extent of
safety problems and inappropriate claims being made for
supplements in the market. Congress could use the survey as a
barometer to judge the extent and severity of the problem in
order to determine the level of resources and fees needed.
The substantiation assurance fees could be based on the
notification filed by supplement manufacturers for new claims
as required by DSHEA.190 Although the fee would be flat, there
should be some differentiation between the fees charged small
businesses and other businesses.
5. Substantiation Model versus Food Additive Model
The substantiation model now seems a more relevant model
for determining the safety of supplements than the food additive
model of pre-market approval. The risk-benefit determinations
called for warnings about the lack of substantiation for cosmetics. 21 C.F.R. § 740.10
(2000). See also Herbal Remedies, supra note 1, at 703.
188. David A. Kessler, Editorial, Cancer and Herbs, 342 NEW ENG. J. OF MED. 1742,
1743 (2000).
189. 21 U.S.C. § 379(h) (1994 & Supp. III 1997).
190. 21 U.S.C. § 343(r)(6) (1994).
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the FDA intends to make for supplements are not typically
made for food additives. 191 Moreover, if Congress were to repeal
the food additive exemption, the legislation would likely provide
a transition period, or grandfathering, which would make pre-
market approval generally irrelevant.
6. Priorities for Substantiation
The FDA should identify which aspects of safety
substantiation need to be addressed first if an obligation to
substantiate is established. Presumably, the need for
substantiation is greatest with respect to supplements for which
serious adverse reactions have occurred, supplements with
ingredients that have a potential for risks, supplements used for
long periods by large numbers, and supplements for which no
regularized substantiation review program has been
undertaken. The agency should identify its priorities for taking
enforcement action and for investigating whether the
substantiation obligation has been met. While only advisory, a
clear statement by the agency of its enforcement policy can
provide for a transition in the initial years of implementation
and reduce resistance to a recognition of the obligation. 192
7. Commercial Free Speech and Safety Substantiation
When the Pearson court found that commercial free speech
permitted health claims for supplements with disclaimers, the
court took particular notice that there was no dispute about the
safety of the supplements. 193 The supplements at issue in that
case were nutritional supplements, the only type eligible by
statute to make health claims, and their safety was not an
issue. 194 Safety is more problematic when claims are made for
herbal supplements, without a history of food use, and safety
needs more consideration if commercial free speech were ever
extended to disease claims or other claims for herbal non-
nutritive supplements.
The safety of supplements clearly constitutes a substantial
191. Diethylstilbestrol: Withdrawal of Approval of New Animal Drug Application,
44 Fed. Reg. 54,851, 54,882-83 (1979) (disavowing earlier FDA position that benefits are
considered in determining the safety of food additives).
192. Compare Part II.D.
193. Pearson v. Shalala, 164 F.3d 650, 655-56 (1999). See also infra Part IV.A.




Montana Law Review, Vol. 62 [2001], Iss. 1, Art. 3
https://scholarship.law.umt.edu/mlr/vol62/iss1/3
DIETARY SUPPLEMENTS
government interest. Congress' authority to require pre-market
approval to ensure safety does not seem open to challenge. 195
Some may question whether Congress can adopt a safety
substantiation model that puts the burden on the manufacturer
to have affirmative proof that the product is safe. If raised, that
contention should be rejected. Placing the substantiation
requirement on the manufacturer directly promotes the
government's interest in protecting the public health. The
means used must also constitute a reasonable fit in achieving
the goal, but the means need not be the least restrictive. 196
While the use of a court enforcement model has lesser burdens
for manufacturers, a safety substantiation model provides a
better assurance of safety by recognizing the affirmative
obligation of manufacturers to determine that the products are
safe when ingested. The burden the FDA has in using an
enforcement model indicates the need for better means to
safeguard the public health and prevent deception.
VII. CONCLUSION
DSHEA is an experiment in deregulation. It creates what
the FDA has called "a unique regulatory regime."197  The
products are not regulated as rigorously as either foods or drugs.
It is an imperfect law because of the peculiarity of calling herbal
products "dietary" when they have no food use, and the claims
relate to the effects of drugs. DSHEA is an oblique way of
providing freedom-of-choice to consumers who may use the
products for unproven disease purposes indirectly suggested by
the labeling.
The FDA, by rule, has recognized a wide number of claims
as permissible structure and function claims for supplements.
Some of the claims are vague, like supporting mood or
maintaining cardiovascular function. The FDA recognizes that
some claims, such as maintaining the immune system, relate to
disease and non-disease functions. Some permitted claims deal
with the effects of life stages, like hair loss, absentmindedness,
or decreased sexual function. In drawing the disease line, the
FDA was influenced by the generality of the claim, the lack of
references to specific disease symptoms, and the need to avoid
195. For constitutional test, see Central Hudson Gas & Elec. Co. v. Public Serv.
Comm'n, 447 U.S. 557 (1980). See also Constitutionalizing, supra note 4, at 823-28.
196. Board of Trustees v. Fox, 492 U.S. 469, 480 (1989).
197. Final Claims Rule, 65 Fed. Reg. at 1002.
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safety risks which arise if a claim deters treatment for serious
conditions beyond the ability of the consumer to judge.
The generality of some of the claims permitted can still
confuse consumers and indirectly suggest the need for use to
prevent disease. Many claims should have been more specific in
identifying that the supplement use is for a minor condition or
for maintaining a normal physical function which the consumer
can ascertain and understand.
The most serious problem with DSHEA is that it is an
experiment in the use of supplements when their safety is not
well known. The FDA bears the burden of proving that
supplements are unsafe. Instead, manufacturers should be
required to substantiate the safety of all supplements. The
agency's inconclusive effort to regulate ephedrine illustrates the
challenges in determining safety and the need to identify and
communicate effectively the limits of permissible uses. 198
The substantiation model has a potential for being an
appropriate alternative scheme for regulating both the safety of
supplements and the validity of non-disease claims.
Substantiation involves neither the delays to the industry of
pre-market review, nor the drawbacks to the public of making
the government, rather than the manufacturer, affirmatively
prove a supplement works and is safe. But to make the
intermediate substantiation model work, the FDA needs to have
clear and enforceable authority to require substantiation.
Requiring manufacturers to pay the government a
substantiation assurance fee is a way to provide needed
resources to help enforce the law. Without adequate resources
and authority, the substantiation obligation can be an empty
shell.
A disclosure model has been allowed for health claims on
supplements on constitutional grounds. Supplements can make
the health claim with a disclosure about the inconclusiveness of
the studies, and the lack of FDA approval, even if the
supplement does not have the support or scientific recognition
otherwise required. 9 9 When disclosures relate to claims which
rely on scientific testing and recognition, the disclosure should
indicate that the determination goes beyond a lay judgment and
needs expert scientific support. Thus, consumers should be
informed about the lack of significant scientific approval for the
198. See Part VI.B.3.
199. Pearson v. Shalala, 164 F.3d 650 (1999). See also supra Part IV.A.
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claim. Formulating what needs to be said in disclosures
involves a judgment about how important science is as the
standard of reliability.
The FDA's efforts to regulate supplements since DSHEA
provide some examples of the collaborative approach which has
been suggested as a model for administrative governance. The
FDA holds public meetings and involves "stakeholders" in
developing rules. 200 At a more basic substantive level, the
expansiveness of the claims for supplements allowed in the FDA
rule can be seen as a pragmatic effort at problem solving in light
of Congress' interest in broadening the claims allowed. The
agency has had to come to terms with a statutory change which
permits a greater role for consumer choice for an ambiguous
category of supplement claims.
Some vision needs to guide the agency's response to
objections to regulatory proposals and collaborative efforts, if the
agency's role is to be something more than splitting the
difference with the most persistent, or avoiding litigation and
trouble with Congress. The agency has a role which goes beyond
that of private participants in a negotiation.20 1 The agency has a
mission to promote the goals identified by Congress in the law.
If the agency's core role becomes that of achieving consensus
with private parties and regulated entities, the statutory scheme
in practice is likely to be deregulated, without Congress having
to assume the responsibility to the public for that decision.
The agency, though, is not simply an implementer of clear
statutory directions. The food and drug laws have, for purposes
of interpretation, been described "as a constitution", and the
agency is to develop "whatever innovative and creative
regulatory programs are reasonable and most appropriate to
achieve the fundamental objectives laid down by Congress."20 2
This view of the scope of the delegation is consistent with seeing
the agency as a problem-solver whose goal is to consider new
approaches to deal with emerging concerns in a way consistent
with the overall statutory aims.20 3
200. The agency has set forth its "Dietary Supplement Strategy," which included
public meetings on the plan, regulations, "FDA's new and continued partnerships with
other government agencies, academia, health professionals, industry, and consumers,"
and continued "outreach to stakeholders." <http:/ /vm.cfsan.fda.gov/ldmslds-
strat.html>.
201. Funk, supra note 13, at 1356.
202. Peter Barton Hutt, Philosophy of Regulation Under the Federal Food, Drug
and Cosmetic Act, 28 FOOD, DRUG, COSMETIC L.J. 177 (1973).
203. See Mashaw supra note 14, at 156 (delegation to expert agencies "becomes a
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With respect to dietary supplements, Congress has given an
ambiguous and difficult task to the agency. While the agency's
power has been reduced, Congress did not adopt a laissez-faire
approach. The supplements are still regulated within the
framework of FDA responsibilities as a scientific and public
health agency. The agency has to sort out how to let consumers
have access to supplements while ensuring that supplements do
what they claim to do, and do not pose a public health risk.
The agency needs to re-formulate how its core statutory
mission is at stake in a way which will have public acceptance.
The identification of safety concerns as a major purpose behind
the rules on supplement claims helps to provide a useful guide.
The safety concerns are strongest when they relate to risks of
harm like those associated with prescription drugs, and claims
for serious conditions beyond the ability of the consumer to
judge without medical advice. Even in a deregulatory statute
which promotes consumer choice, the potential to cause serious
harm is a risk against which the public needs and, presumably,
still wants protection.
Moreover, given the regulatory philosophy which
emphasizes consumer choice, more attention needs to be given to
the type of specific information consumers need to make
informed choices. One challenge is whether it is possible to
develop adequate information to educate lay consumers. The
other challenge is dealing with resistance to better labeling.
The adequacy of labeling, and the adequacy of the agency
enforcement resources, promise to be the new battlefield in
determining whether there is an adequate "third way" to
regulate and deregulate consumer products like dietary
supplements.
form of consensus building that, far from taking decisions out of politics, seeks to give
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